Biotech Values

[iwfal]

CLDX -

Again to minimize the drug's mechanism of action in later trial only works after you have right sample size to draw better conclusion. This isn't the case here.

I would suggest the sample size, small though it is, is adequate to largely reject (see previous post with WAG'd math) the hypothesis that the drug works meaningfully in refractory BC HG wo TN. Which is precisely why I deweight the MOA - even small trials can rule out the large efficacy results you need to see in surrogate endpoints in order to get acceptable results in OS.


Or you disagree with the math I gave in an earlier post #msg-76005421 ?